Deciphera Pharmaceuticals Inc (DCPH)
25.54
+0.01
(+0.04%)
USD |
NASDAQ |
May 31, 16:00
25.54
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Research and Development Expense (TTM): 237.19M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 237.19M |
| December 31, 2023 | 234.12M |
| September 30, 2023 | 223.59M |
| June 30, 2023 | 208.61M |
| March 31, 2023 | 195.17M |
| December 31, 2022 | 187.82M |
| September 30, 2022 | 214.69M |
| June 30, 2022 | 233.64M |
| March 31, 2022 | 248.77M |
| December 31, 2021 | 257.04M |
| September 30, 2021 | 234.40M |
| June 30, 2021 | 217.17M |
| March 31, 2021 | 203.26M |
| December 31, 2020 | 198.97M |
| Date | Value |
|---|---|
| September 30, 2020 | 193.32M |
| June 30, 2020 | 184.48M |
| March 31, 2020 | 173.21M |
| December 31, 2019 | 157.61M |
| September 30, 2019 | 138.33M |
| June 30, 2019 | 118.59M |
| March 31, 2019 | 101.75M |
| December 31, 2018 | 82.89M |
| September 30, 2018 | 71.19M |
| June 30, 2018 | 60.31M |
| March 31, 2018 | 50.78M |
| December 31, 2017 | 39.51M |
| September 30, 2017 | 30.39M |
| June 30, 2017 | 25.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
118.59M
Minimum
Jun 2019
257.04M
Maximum
Dec 2021
203.00M
Average
205.94M
Median
Research and Development Expense (TTM) Benchmarks
| Bristol-Myers Squibb Co | 9.673B |
| Dynavax Technologies Corp | 54.81M |
| Gilead Sciences Inc | 8.222B |
| Esperion Therapeutics Inc | 68.13M |
| SINTX Technologies Inc | 8.516M |